scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to improve the delivery of infused therapies and develop patient care. Co.'s product, FUROSCIX®, consists of its formulation of furosemide delivered via West Pharmaceutical Services, Inc.'s on-body infusor, and is used for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX is a subcutaneous loop diuretic that delivers intravenous equivalent diuresis at home. The SCPH stock yearly return is shown above.
The yearly return on the SCPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SCPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|